Early detection of relapse and early therapeutic intervention: The benefits of Devyser NGS method for chimerism analysis
A better patient care is the final objective for Dr. Helena Devos and the team at Sint Jan’s...
We are excited to announce that we will be attending the cfDNA2023 conference. The meeting promises to provide an excellent overview of the field as presented by key experts and give us the opportunity to discuss scientific and clinical topics with peers from the field. We look forward to learning from and contributing to the conversation at cfDNA2023.
“During early pregnancy, 3-6% of cell-free DNA in the plasma of pregnant women is of fetal origin.”
Dr. Agneta Wikman, M.D., Ph.D, Karolinska University Hospital, Stockholm, Sweden
Choosing and implementing the best screening method for non-invasive fetal-RHD testing. Learn from clinical experts about the shift in today’s screening method for non-invasive fetal-RHD testing. Dr Wikman is a professor and specialist in Transfusion Medicine and Laboratory Medicine.
News | May 8, 2023
Devyser winner of Swecare Export Awards 2023News | April 24, 2023
Devyser enters agreement with Thermo Fisher Scientific for commercialization of Devyser’s post-transplant NGS productsNews | March 1, 2023
Devyser launches first IVDR-certified productA better patient care is the final objective for Dr. Helena Devos and the team at Sint Jan’s...
Read More
As a lab manager, you know the importance of streamlining workflows to maximize productivity and...
Read More
With new more sensitive diagnostics, rejection of a transplanted kidney can be detected earlier,...
Read More
Hematopoietic stem cell transplantation (HSCT) is the only curative treatment for patients with...
Read More